Brief: Alkermes Announces Positive Topline Results From Phase 1B Study Of ALKS 2680

Alkermes

09/04/2024 12:27

April 9 (Reuters) - Alkermes Plc  ALKS.O :
    * ALKERMES ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 1B
STUDY
OF ALKS 2680 DEMONSTRATING IMPROVED WAKEFULNESS IN PATIENTS WITH
NARCOLEPSY TYPE 2 AND IDIOPATHIC HYPERSOMNIA
    * ALKERMES PLC: ALKS 2680 WAS GENERALLY WELL TOLERATED AT
ALL
DOSES TESTED
    * ALKERMES PLC: DOSE-DEPENDENT EFFECTS AND PHARMACODYNAMIC
PROFILE
SUPPORT ADVANCEMENT INTO PLANNED PHASE 2 STUDY
    * ALKERMES: ALKS 2680 DEMONSTRATED CLINICALLY MEANINGFUL &
STATISTICALLY SIGNIFICANT IMPROVEMENTS FROM BASELINE IN MEAN
SLEEP LATENCY
    * ALKERMES PLC: PLANS TO INITIATE A PHASE 2 STUDY IN
PATIENTS WITH
NT2 IN SECOND HALF OF 2024

Source text for Eikon:  ID:nPnK1kb5a 
Further company coverage:  ALKS.O 

 ((Reuters.Briefs@thomsonreuters.com;))